A systematic review of cooling for neuroprotection in neonates with hypoxic ischemic encephalopathy - are we there yet?

Department of Neonatal Paediatrics, Women's and Children's Health Service, Perth, Australia.
BMC Pediatrics (Impact Factor: 1.92). 09/2007; 7:30. DOI: 10.1186/1471-2431-7-30
Source: PubMed

ABSTRACT The objective of this study was to systematically review randomized trials assessing therapeutic hypothermia as a treatment for term neonates with hypoxic ischemic encephalopathy.
The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL databases, reference lists of identified studies, and proceedings of the Pediatric Academic Societies were searched in July 2006. Randomized trials assessing the effect of therapeutic hypothermia by either selective head cooling or whole body cooling in term neonates were eligible for inclusion in the meta-analysis. The primary outcome was death or neurodevelopmental disability at >or= 18 months.
Five trials involving 552 neonates were included in the analysis. Cooling techniques and the definition and severity of neurodevelopmental disability differed between studies. Overall, there is evidence of a significant effect of therapeutic hypothermia on the primary composite outcome of death or disability (RR: 0.78, 95% CI: 0.66, 0.92, NNT: 8, 95% CI: 5, 20) as well as on the single outcomes of mortality (RR: 0.75, 95% CI: 0.59, 0.96) and neurodevelopmental disability at 18 to 22 months (RR: 0.72, 95% CI: 0.53, 0.98). Adverse effects include benign sinus bradycardia (RR: 7.42, 95% CI: 2.52, 21.87) and thrombocytopenia (RR: 1.47, 95% CI: 1.07, 2.03, NNH: 8) without deleterious consequences.
In general, therapeutic hypothermia seems to have a beneficial effect on the outcome of term neonates with moderate to severe hypoxic ischemic encephalopathy. Despite the methodological differences between trials, wide confidence intervals, and the lack of follow-up data beyond the second year of life, the consistency of the results is encouraging. Further research is necessary to minimize the uncertainty regarding efficacy and safety of any specific technique of cooling for any specific population.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A hipotermia induzida é uma terapêutica neuroprotectora com segurança e eficácia demonstradas no tratamento de recém-nas - cidos de termo com encefalopatia hipoxico-isquémica (EHI). Consiste na redução da temperatura corporal para uma tempe- ratura alvo entre 33 e 34°C durante 72 horas, e é considerada no momento actual a terapêutica de eleição na EHI moderada a grave, já existindo experiência considerável na sua utilização em contexto cl'inico. Deste modo, é crucial que todos os médicos que prestam assis tência ao recém-nascido conheçam as indicações para este tratamento e as especificidades da abordagem inicial des- tes recém-nascidos, sendo essencial, no local de nascimento e no transporte, a monitorização cuidada da temperatura e a ins- tituição de medidas de hipotermia passiva. O primeiro programa nacional de hipotermia induzida na EHI iniciou-se no Serviço de Neonatologia do Hospital de Santa Maria em Novembro de 2009, que dispõe de uma localização geográfica central no pa'is e do apoio multidisciplinar neces- sário para a abordagem mais adequada a estes doentes. A apli- cação desta técnica tem especificidades relacionadas com a gravidade cl'inica dos doentes tratados e com a interferência da hipotermia na fisiopatologia dos vários sistemas. Palavras Chave: Hipotermia, encefalopatia hipóxico-isqué- mica, neuroprotecção Acta Pediatr Port 2010;41(4):184-90 Therapeutic hypothermia in hypoxic-isch
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic hypothermia is the standard clinical practice for neonates with moderate to severe hypoxic ischaemic encephalopathy (HIE). Aim To describe the two year neurodevelopmental outcomes of neonates who were routinely cooled using cool gel packs for HIE in Western Australia Methods Retrospective study. Cases were identified from the neonatal databases. Information was collected from chart review Results 65 infants received therapeutic hypothermia, of which 13 had mild, 35 moderate and 17 had severe HIE. There were no serious adverse effects attributable to cooling. All 13 infants with mild HIE survived, of whom developmental outcomes were available on nine; none had severe disability. Among 52 infants with moderate to severe HIE, there were nine deaths (17%) and developmental outcomes were available on 39; the incidence of severe disability was 23%. The risk of death or severe disability was 40% in infants with moderate to severe HIE. Physical growth was adequate at two years of age Conclusions Neonates undergoing therapeutic hypothermia with cool gel packs had both good survival rates and long term neurodevelopmental outcomes and met international benchmarks.
    European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 05/2014; 18(3). DOI:10.1016/j.ejpn.2014.02.003 · 1.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypothermia can reduce neurodevelopmental disabilities in asphyxiated newborn infants. However, the optimal cooling temperature for neuroprotection is not well defined. We studied the effects of transient piglet brain hypoxic ischemia (HI) on transcriptional activity of eight genes and if mRNA level alterations could be counteracted by whole body cooling to 35, 33.5 or 30 °C. BDNF mRNA was globally upregulated by the insult, and none of the cooling temperatures counteracted this change. In contrast, MANF mRNA was downregulated, and these changes were modestly counteracted in different brain regions by hypothermic treatment at 33.5 °C, while 30 °C aggravated the MANF mRNA loss. MAP2 mRNA was markedly downregulated in all brain regions except striatum, and cooling to 33.5 °C modestly counteract this downregulation in the cortex cerebri. There was a tendency for GFAP mRNA levels in core, but not mantle regions to be downregulated and for these changes to be modestly counteracted by cooling to 33.5 or 35 °C. Cooling to 30 °C caused global GFAP mRNA decrease. HSP70 mRNA tended to become upregulated by HI and to be more pronounced in cortex and CA1 of hippocampus during cooling to 33.5 °C. We conclude that HI causes alterations of mRNA levels of many genes in superficial and deep piglet brain areas. Some of these changes may be beneficial, others detrimental, and lowering body temperature partly counteracts some, but not all changes. There may be general differences between core and mantle regions, as well as between the different cooling temperatures for protection. Comparing the three studied temperatures, cooling to 33.5 °C, appears to provide the best cooling temperature compromise.
    Translational Stroke Research 04/2013; 4(2):248-57. DOI:10.1007/s12975-012-0215-4 · 1.94 Impact Factor

Full-text (3 Sources)

Available from
Jun 2, 2014